0 CHECKOUT

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2015

  • ID: 3275738
  • May 2015
  • 55 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Actavis plc
  • EndoCeutics, Inc.
  • MediGene AG
  • Pantarhei Bioscience BV
  • Peptonic medical AB
  • RestorGenex Corporation
  • MORE

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2015

Summary

The‘Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2015’, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actavis plc
  • EndoCeutics, Inc.
  • MediGene AG
  • Pantarhei Bioscience BV
  • Peptonic medical AB
  • RestorGenex Corporation
  • MORE

List of Tables

List of Figures

Introduction

Report Coverage

Vaginal Atrophy (Atrophic Vaginitis) Overview

Therapeutics Development

Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview

Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Comparative Analysis

Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies

Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development

Actavis plc

EndoCeutics, Inc.

Foamix Pharmaceuticals Ltd.

MediGene AG

Pantarhei Bioscience BV

Peptonic medical AB

RestorGenex Corporation

TherapeuticsMD Inc.

Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

esterol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

estradiol hemihydrate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

oxytocin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

prasterone - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RES-102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sinecatechins - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TX-004HR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

WC-3011 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaginal Atrophy (Atrophic Vaginitis) - Recent Pipeline Updates

Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects

Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones

Featured News & Press Releases

Mar 09, 2015: Physicians Visual Assessments Correlate with Objective Measurements of Postmenopausal VVA Patients Treated with TX-004HR VagiCap

Feb 20, 2015: Survey Shows Postmenopausal Women with VVA Reported Improved Satisfaction and Quality of Life with VagiCap Investigational Local Estrogen Treatment

Oct 28, 2014: First patients included in Peptonic Medical AB’s clinical phase 2b study

Oct 15, 2014: TherapeuticsMD Announces Oral Presentation of Positive Phase 2 and Bioavailability Data on TX-004HR (VagiCap)

Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study

Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study

Apr 07, 2014: Therapeutics MD Reports Positive Results of Rabbit Irritation Study for Its Estradiol Vaginal Capsule VagiCap (TX 004-HR) for Treatment of Vulvar Vaginal Atrophy

Jan 28, 2014: TherapeuticsMD Reports Positive PK Study Results for Its Estradiol Vaginal Capsule VagiCap (TX 12-004-HR) for Treatment of Vulvar Vaginal Atrophy

Oct 22, 2013: TherapeuticsMD Phase 1 Pilot Study Shows TX-12-004-HR Estradiol VagiCap Improves Conditions of Vulvar and Vaginal Atrophy

Aug 12, 2013: TherapeuticsMD commences Phase I study of vulvar and vaginal atrophy candidate

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2015

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis) - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Comparative Analysis by Late Stage Development, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Development, H1 2015

Products under Development by Companies, H1 2015

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Actavis plc, H1 2015

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by EndoCeutics, Inc., H1 2015

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by MediGene AG, H1 2015

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Pantarhei Bioscience BV, H1 2015

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Peptonic medical AB, H1 2015

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by RestorGenex Corporation, H1 2015

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc., H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Stage and Target, H1 2015

Number of Products by Stage and Mechanism of Action, H1 2015

Number of Products by Stage and Route of Administration, H1 2015

Number of Products by Stage and Molecule Type, H1 2015

Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Recent Pipeline Updates, H1 2015

Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H1 2015

List of Figures:

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2015

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis) - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Top 10 Targets, H1 2015

Number of Products by Stage and Top 10 Targets, H1 2015

Number of Products by Top 10 Mechanism of Actions, H1 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015

Number of Products by Top 10 Routes of Administration, H1 2015

Number of Products by Stage and Top 10 Routes of Administration, H1 2015

Number of Products by Top 10 Molecule Types, H1 2015

Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Actavis plc
- EndoCeutics, Inc.
- Foamix Pharmaceuticals Ltd.
- MediGene AG
- Pantarhei Bioscience BV
- Peptonic medical AB
- RestorGenex Corporation
- TherapeuticsMD Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Actavis
  • Smith & Nephew PLC.
  • Bayer AG
  • Hologic Inc.
  • Abbott Laboratories Ltd.
  • Polpharma SA